Sai Life Sciences reported audited FY26 results with revenue from operations at ₹2,192 Cr, a 29% YoY increase from ₹1,695 Cr.
EBITDA grew 56% YoY to ₹661 Cr, while PAT before exceptional items more than doubled to ₹355 Cr, a 109% increase.
The company incurred a capital expenditure of ₹633 Cr during the year to support growth and capability expansion.
An earnings call is scheduled for 15 May 2026 at 4:00 PM IST to discuss the financial and business performance.